Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Anticipating Limoneiras Quarterly Earnings Analyst Expectations and Stock Performance

Elaine Mendonca by Elaine Mendonca
March 6, 2024
in Breaking News
0
Finance_ stocks to buy
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Limoneira (NASDAQ: LMNR) is set to announce its quarterly earnings on March 7, 2024. Analysts are anticipating an EPS of $-0.29. Investors are eagerly awaiting the results to see if Limoneira will exceed expectations and provide positive guidance for the next quarter, as guidance tends to have a greater impact on stock prices than earnings beats or misses.

Looking back at previous quarters, Limoneira has had mixed results:
– Q4 2023: EPS Estimate -0.15, Actual -0.15, Price Change +7.00%
– Q3 2023: EPS Estimate 0.15, Actual 0.02, Price Change -4.0%
– Q2 2023: EPS Estimate 0.19, Actual 0.21, Price Change -8.0%
– Q1 2023: EPS Estimate -0.35, Actual -0.53, Price Change +5.0%.

As of March 5, Limoneira’s shares were trading at $17.91, showing a positive return of 13.13% over the past year. This indicates a favorable performance for long-term shareholders leading up to the upcoming earnings release.

Investors looking for more detailed forecasts and price targets for Limoneira stock can find information on TipRanks.

This data gives investors insight into what to expect from Limoneira’s upcoming earnings report and how past performance and analyst estimates can impact stock prices.

Limoneira Company (LMNR) Shows Stability and Positive Momentum in Stock Performance

On March 6, 2024, Limoneira Company (LMNR) showed signs of stability and positive momentum in its stock performance. According to data from CNN Money, LMNR was trading in the middle of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been relatively stable over the long term and is currently in a favorable position compared to historical averages.

LMNR opened at $17.90, which was $0.01 lower than its previous close. By the market’s close, LMNR had increased by $0.01, representing a 0.06% rise in its share price. This modest gain may seem small, but it is a positive sign for investors as it demonstrates that the stock was able to maintain its upward momentum despite the initial dip in the morning.

Overall, the performance of LMNR on March 6, 2024, can be seen as a reflection of the company’s stability and potential for growth. Investors may view LMNR as a promising investment opportunity, but it is important for investors to conduct their own research and analysis before making any decisions.

LMNR Stock Performance Analysis: Revenue Flat, Net Income Surges, EPS Drops

On March 6, 2024, LMNR stock experienced fluctuations in its performance based on the financial data provided by CNN Money. The company’s total revenue for the past year was reported at $179.90 million, which remained flat compared to the previous year. However, there was a significant decrease of 21.08% in total revenue since the last quarter, with the figure standing at $41.43 million.

In terms of net income, LMNR reported a net income of $9.25 million for the past year, marking a substantial increase of 3335.66% compared to the previous year. However, the net income took a hit in the last quarter, with a reported loss of $3.41 million, representing a decrease of 186.3% since the previous quarter.

Furthermore, the earnings per share (EPS) for LMNR stood at $0.50 for the past year, showing a significant increase of 1207.35% compared to the previous year. However, the EPS dropped to -$0.20 in the last quarter, indicating a decrease of 168.63% since the previous quarter.

These financial metrics reflect the mixed performance of LMNR stock on March 6, 2024. While the company saw significant improvements in net income and EPS compared to the previous year, there was a notable decline in total revenue and profitability in the last quarter. Investors and analysts may closely monitor these financial indicators to assess the company’s overall financial health and future prospects.

Tags: LMNR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Banking (2)

Anticipating CITs Quarterly Earnings Report Analyst Expectations and Historical Performance

5G Network

Bearish Sentiment Towards Goldman Sachs Revealed Through Recent Options Trading Activity

Finances and charts

Analyst Reaffirms Bullish Outlook on NeuroPace with Increased Price Target

Recommended

Amazon Stock

Amazon’s AI Investment Strategy Yields Early Dividends

3 months ago
CVR Energy Stock

CVR Energy Shares Soar on Geopolitical Tensions Despite Analyst Caution

2 months ago
Biotechnology Stock Exchange

Anticipation Builds for CoDiagnostics Quarterly Earnings Report

2 years ago
Chindata Holdings Stock

Bain Capital Divests $4 Billion Chinese Data Center Portfolio in Landmark Deal

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

DuPont Faces Critical Test as Quarterly Results Loom

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

Trending

Analysis

BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise

by Andreas Sommer
November 6, 2025
0

BioNTech presents investors with a complex financial picture marked by contradictory signals. The German biotech firm reported...

Illumina Stock

China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally

November 6, 2025
Iovance Stock

Iovance Faces Critical Test as Q3 Earnings Approach

November 6, 2025
DuPont de Nemours Stock

DuPont Faces Critical Test as Quarterly Results Loom

November 6, 2025
Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise
  • China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally
  • Iovance Faces Critical Test as Q3 Earnings Approach

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com